Hyperreflective Foci Precede Macular Neovascularization Formation in Angioid Streaks.

The aim of this study was to report unusual progression of type 2 macular neovascularization (MNV) associated with age-related macular degeneration (AMD), high myopia or angioid streaks. Retrospective multicentric observational case series data were used. Eyes that progressed from type 2 MNV secondary to AMD, high myopia or angioid streaks to fibrovascular pigment epithelial detachment (PED) were included. A total of 29 treatment-naive eyes from 29 patients with type 2 MNV secondary to AMD (n = 14), high myopia (n = 10) or angioid streaks (n = 5) that progressed to a fibrovascular PED on Spectral Domain-Optical Coherence Tomography were used. This progression occurred within 3 months after anti-VEGF therapy initiation. Logarithm of minimum angle of resolution (LogMAR) visual acuity improved significantly after anti-VEGF therapy, from 0.55 (SD ± 0.30) (20/63–20/80) at baseline to 0.30 (20/40) at 3 months, and 0.33 (20/40) at the final follow-up (mean follow up: 3.68 years). Mean number of intravitreal injections per year for patients with a total follow-up ≥ 12 months (n = 24) was 4.3 ± 2.1 per year. Progression from type 2 MNV to a fibrovascular PED may occur in patients suffering from AMD, high myopia or angioid streaks. This progression appears early after initiation of anti-VEGF therapy and is associated with a favorable visual and anatomical outcome, at least on a short follow up basis.

Download Full-text

Novel mutations of ABCC6 gene in Japanese patients with Angioid streaks

Biochemical and Biophysical Research Communications ◽

10.1016/j.bbrc.2009.01.117 ◽

2009 ◽

Vol 380 (3) ◽

pp. 548-553 ◽

Cited By ~ 14

Author(s):

Naoyuki Sato ◽

Tomohiro Nakayama ◽

Yoshihiro Mizutani ◽

Mitsuko Yuzawa

Keyword(s):

Japanese Patients ◽

Angioid Streaks ◽

Novel Mutations ◽

Abcc6 Gene

Download Full-text

Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy

Scientific Reports ◽

10.1038/s41598-021-84553-7 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Chu-Hsuan Huang ◽

Chang-Hao Yang ◽

Yi-Ting Hsieh ◽

Chung-May Yang ◽

Tzyy-Chang Ho ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Visual Acuity ◽

Growth Factor ◽

Treatment Response ◽

Macular Oedema ◽

Diabetic Macular Oedema ◽

Vascular Endothelial ◽

Outer Retina ◽

Hyperreflective Foci ◽

Endothelial Growth Factor

AbstractThis retrospective study evaluated the association of hyperreflective foci (HRF) with treatment response in diabetic macular oedema (DME) after anti-vascular endothelial growth factor (VEGF) therapy. The medical records, including of ophthalmologic examinations and optical coherence tomography (OCT) images, of 106 patients with DME treated with either intravitreal ranibizumab or aflibercept were reviewed. The correlations between best-corrected visual acuity (BCVA) changes and HRF along with other OCT biomarkers were analysed. The mean logMAR BCVA improved from 0.696 to 0.461 after an average of 6.2 injections in 1 year under real-world conditions. Greater visual-acuity gain was noted in patients with a greater number of HRF in the outer retina at baseline (p = 0.037), along with other factors such as poor baseline vision (p < 0.001), absence of epiretinal membrane (p = 0.048), and presence of subretinal fluid at baseline (p = 0.001). The number of HRF after treatment was correlated with the presence of hard exudate (p < 0.001) and baseline haemoglobin A1C (p = 0.001). Patients with proliferative diabetic retinopathy had greater HRF reduction after treatment (p = 0.018). The number of HRF in the outer retina, in addition to other baseline OCT biomarkers, could be used to predict the treatment response in DME after anti-VEGF treatment.

Download Full-text